Brief: Dermata Therapeutics Inc - End Of Phase 2 Meeting With FDA For Dmt310 For Moderate-To-Severe Acne Expected In 2Q 2023

Dermata Therapeutics

21/02/2023 22:23

Feb 21 (Reuters) - Dermata Therapeutics Inc  DRMA.O :
    * DERMATA THERAPEUTICS INC - END OF PHASE 2 MEETING WITH FDA
FOR
DMT310 FOR MODERATE-TO-SEVERE ACNE EXPECTED IN 2Q 2023
    * DERMATA THERAPEUTICS INC - AS OF DEC 31, 2022, CO HAD $6.2
MILLION IN CASH AND CASH EQUIVALENTS, COMPARED TO $10.8 MILLION
AS OF DECEMBER 31, 2021
    * DERMATA THERAPEUTICS - EXPECTS ITS CURRENT CASH RESOURCES
ARE
SUFFICIENT TO FUND OPERATIONS INTO 3Q 2023

Further company coverage:  DRMA.O 
 ((Reuters.Briefs@thomsonreuters.com;;))